Marinus Pharma Agrees To $151 Million Acquisition By Immedica
Deal News | Dec 30, 2024 | EIN
Marinus Pharmaceuticals, Inc. is set to be acquired by Immedica Pharma AB in a deal valued at approximately $151 million. Immedica will launch a tender offer to purchase Marinus's common stock at $0.55 per share, a significant premium over previous trading prices. The Marinus Board of Directors has given unanimous approval for the transaction. Immedica's acquisition includes global rights to ZTALMY, a rare neurology medicine, and is anticipated to close in the first quarter of 2025. This deal is expected to enhance Immedica’s revenue through the addition of a U.S. based commercial asset with potential for global expansion.
Sectors
- Pharmaceuticals
- Biotechnology
- Healthcare M&A
Geography
- United States – Marinus Pharmaceuticals is based in the U.S., and ZTALMY, the medicine involved in the acquisition, has been approved by the FDA.
- Sweden – Immedica Pharma AB, the acquiring entity, is a Swedish company, which indicates international M&A activity.
- Global – The deal involves potential global expansion opportunities for ZTALMY, highlighting the impact across multiple jurisdictions.
Industry
- Pharmaceuticals – Relevant as both Marinus Pharmaceuticals and Immedica Pharma operate within the pharmaceutical industry, focusing on drug development and commercialization.
- Biotechnology – The acquisition involves ZTALMY, a rare neurology medicine, which is a significant pharmaceutical asset developed through biotechnology.
- Healthcare M&A – The article centers around an acquisition within the healthcare sector, aligning with merger and acquisition activity frequently seen in this industry.
Financials
- $151 million – Enterprise value of the acquisition deal between Immedica Pharma and Marinus Pharmaceuticals.
- $0.55 per share – Price offered by Immedica Pharma for each share of Marinus common stock, including a significant premium.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Marinus Pharmaceuticals, Inc. | Target Company | Company | A U.S.-based pharmaceutical company being acquired, known for its rare neurology medicine ZTALMY. |
| Immedica Pharma AB | Bidding Company | Company | A Swedish pharmaceutical company acquiring Marinus, focused on specialty pharma and rare disease treatments. |
| Scott Braunstein | CEO of Marinus | Person | Chairman and CEO of Marinus Pharmaceuticals, involved in the transaction. |